Enzon’s Oncaspar
Executive Summary
PLA for PEG-L-asparaginase product is "approvable" at FDA, Enzon announces Dec. 3. Oncaspar (pegaspargase) is a polyethylene- glycol modified version of the anti-cancer compound L- asparaginase. It is pending for treatment of acute lymphoblastic leukemia in patients hypersensitive to L-asparaginase.